Nektar Therapeutics Stock Extends Record Rally on Clinical Breakthrough

Shares of Nektar Therapeutics surged to unprecedented heights this week, reaching a new 52-week peak of $61.24 before settling at $60.50 at yesterday’s close. The biopharmaceutical company registered a solid 2.80% daily gain, extending its remarkable upward trajectory driven by encouraging clinical trial outcomes and reinforced analyst confidence.

Financial institutions have responded to recent developments with upgraded assessments. Jefferies maintained its Buy recommendation while raising its price target to $99. Concurrently, Piper Sandler reaffirmed its Overweight stance with a $105 valuation objective. This follows B. Riley Securities’ late-September projection of $105.00. The consensus among research firms remains unanimously positive, with all recommending acquisition of the stock.

The company’s investigational drug, rezpegaldesleukin, received Fast Track designation from the FDA in July 2025 for severe alopecia... Read more...